This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Beijing University of Technology. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Mark Del Borgo: Innovator in Cardiac Fibrosis Treatment
Introduction
Mark Del Borgo is a notable inventor based in Melbourne, Australia. He has made significant contributions to the field of medical science, particularly in the treatment of fibrosis. His innovative approach focuses on the development of compositions and methods that target cardiac fibrosis, a condition that can lead to severe health complications.
Latest Patents
Mark Del Borgo holds a patent for "Angiotensin receptor agonists and uses thereof." This invention relates to compositions, methods, and kits designed for the treatment of fibrosis. Specifically, the patent outlines a method of treating fibrosis in an individual by administering an AT2R selective agonist, thereby providing a targeted approach to managing this condition.
Career Highlights
Mark is affiliated with the Beijing University of Technology, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on treating cardiac fibrosis, showcasing his commitment to improving patient outcomes through scientific advancements.
Collaborations
Mark has collaborated with esteemed colleagues, including Robert Edward Widdop and Marie-Isabel Aguilar. These partnerships have further enriched his research and contributed to the development of effective treatment methodologies.
Conclusion
Mark Del Borgo's contributions to the field of fibrosis treatment highlight his innovative spirit and dedication to medical science. His patent on angiotensin receptor agonists represents a significant step forward in addressing cardiac fibrosis, showcasing the importance of research and collaboration in advancing healthcare solutions.